|本期目录/Table of Contents|

[1]刘四清,张齐武,杨龙江.长效β2受体激动剂联合异丙托溴铵雾化吸入对COPD肺功能的影响[J].中华肺部疾病杂志,2021,(04):456-458.[doi:10.3877/cma.j.issn.1674-6902.2021.04.012]
点击复制

长效β2受体激动剂联合异丙托溴铵雾化吸入对COPD肺功能的影响(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2021年04期
页码:
456-458
栏目:
出版日期:
2021-08-20

文章信息/Info

Title:
-
作者:
刘四清1; 张齐武2; 杨龙江1
266071 青岛,海军青岛特勤疗养中心三区门诊部1 116600 大连,中国人民解放军967医院呼吸科2
Author(s):
-
关键词:
肺疾病; 慢性阻塞性;  长效β2受体激动剂;  异丙托溴铵;  肺功能;  疗效
Keywords:
-
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2021.04.012
摘要:
目的 探讨长效β2受体激动剂联合异丙托溴铵雾化吸入对慢性阻塞性肺病(COPD)肺功能的影响。方法 选取2019年10月至2020年12月我院收治的45例COPD患者为对象,采用异丙托溴铵雾化吸入治疗患者21例为对照组,采用异丙托溴铵雾化吸入联合长效β2受体激动剂治疗的患者24例为观察组。对比两组治疗前后肺功能、血清炎症因子情况,记录两组临床疗效,统计两组药物不良反应发生情况。结果 两组治疗3个月后、治疗后的用力肺活量(FVC)、第一秒用力呼气容积(FEV1)水平均高于治疗前(P<0.05),两组治疗后的FVC、FEV1水平均高于治疗3个月后(P<0.05); 两组治疗前FVC、FEV1水平对比差异均无统计学意义(P>0.05),观察组治疗3个月后、治疗后的FVC、FEV1水平均高于对照组(P<0.05)。两组治疗3个月后、治疗后的可溶性细胞间黏附分子-1(sICAM-1)、转化生长因子-β1(TGF-β1)水平均低于治疗前(P<0.05),两组治疗后的sICAM-1、TGF-β1水平均低于治疗3个月后(P<0.05); 两组治疗前sICAM-1、TGF-β1水平对比差异均无统计学意义(P>0.05),观察组治疗3个月后、治疗后的sICAM-1、TGF-β1水平均低于对照组(P<0.05)。观察组总有效率高于对照组总有效率(P<0.05)。两组总药物不良反应发生率对比差异无统计学意义(P>0.05)。结论 长效β2受体激动剂联合异丙托溴铵雾化吸入可明显改善老年COPD肺功能,降低炎症因子水平,增强临床疗效,且安全性良好。
Abstract:
-

参考文献/References:

1 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
2 Duffy SP, Criner GJ. Chronic obstructive pulmonary disease: Evaluation and management[J]. Med Clin North Am, 2019, 103(3): 453-461.
3 梁振宇, 陈荣昌. 慢性阻塞性肺疾病诊疗指南(2021年修订版)修订历程及思考[J]. 中华结核和呼吸杂志, 2021, 44(3): 165-166.
4 孙永昌. 慢性阻塞性肺疾病在中国基层医疗机构面临的挑战和应对[J]. 中华结核和呼吸杂志, 2020, 43(1): 14-16.
5 Agnihotri NT, Saltoun C. Acute severe asthma(status asthmaticus)[J]. Allergy Asthma Proc, 2019, 40(6): 406-409.
6 Van der Poorten T, De Hert M. Sublingual use of atropine for clozapine-induced sialorrhoea: literature review and two case reports[J]. Tijdschr Psychiatr, 2019, 61(6): 403-410.
7 姚香萍. 布地奈德联合异丙托溴铵治疗慢性阻塞性肺疾病的临床研究[J]. 现代药物与临床, 2019, 34(10): 2985-2989.
8 Arif E, Nihalani D. Beta2-adrenergic receptor in kidney biology: A current prospective[J]. Nephrology, 2019, 24(5): 497-503.
9 Usmani O, Roche N, Marshall J, et al. An innovative corticosteroid/long-acting β2-agonist breath-triggered inhaler: facilitating lung delivery of fluticasone propionate/formoterol fumarate for the treatment of asthma[J]. Expert Opin Drug Deliv, 2019, 16(12): 1367-1380.
10 夏元旦, 杜晓梅, 周 敏, 等. 吸入型长效抗胆碱能药物及吸入型长效β2受体激动剂在慢性阻塞性肺疾病患者中的应用评价[J]. 药学服务与研究, 2019, 19(3): 56-58.
11 Guerreiro I, Soccal PM. COPD and phenotypes[J]. Rev Med Suisse,2019, 15(671): 2082-2086.
12 Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations[J]. Clin Chest Med, 2020, 41(3): 421-438.
13 Perez-Padilla R, Menezes AMB. Chronic obstructive pulmonary disease in latin America[J]. Ann Glob Health, 2019, 85(1): 7-10.
14 Nomura O, Ihara T, Morikawa Y, et al. Metered-dose inhaler ipratropium bromide for children with acute asthma exacerbation: A prospective, non-randomized, observational study[J]. Pediatr Int, 2020, 62(3): 319-323.
15 Derinoz-Guleryuz O, Fidanci I, Men-Atmaca Y. Nebulized ipratropium bromide-induced anisocoria: Why is anisocoria observed[J]. Iran J Allergy Asthma Immunol, 2021, 20(1): 125-128.
16 Pereira Filho FA, Sarni ROS, Wandalsen NF. Evaluation of treatment of the exacerbation of asthma and wheezing in a pediatric emergency department[J]. Rev Assoc Med Bras, 2020, 66(9): 1270-1276.
17 姚萍丽, 嵇利芳. 孟鲁司特钠联合复方异丙托溴铵治疗老年支气管哮喘急性发作患者的疗效及对肺功能和炎症因子的影响[J]. 中国老年学杂志, 2020, 40(11): 80-82.
18 Samarakoon R, Higgins SP, Higgins CE, et al. The TGF-β1/p53/PAI-1 signaling axis in vascular senescence: Role of caveolin-1[J]. Biomolecules, 2019, 9(8): 341-345.
19 Jin J, Togo S, Kadoya K, et al. Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1[J]. Respir Res, 2019, 20(1): 119-122.
20 Ren S, Chen J, Wang Q, et al. MicroRNA-744/transforming growth factor β1 relationship regulates liver cirrhosis[J]. Hepatol Int, 2019, 13(6): 814-825.
21 Wu M, Tong X, Wang D, et al. Soluble intercellular cell adhesion molecule-1 in lung cancer: A meta-analysis[J]. Pathol Res Pract, 2020, 216(10): 1530-1534.
22 Makris S, Venetsanou K, Spartalis E, et al. Changes in serum leptin levels as well as sICAM-1 and sVCAM-1 soluble adhesion molecules during carotid endarterectomy[J]. Eur Rev Med Pharmacol Sci, 2019, 23(5): 2257-2262.
23 Bieuzen F, Hausswirth C, Dugue B. Circulating soluble intercellular adhesion molecule-1(sICAM-1)after exercise-induced muscular damage: Does the use of whole-body cryostimulation influence its concentration in blood[J]. Cryobiology, 2019, 87(1): 120-122.
24 Strzelczyk JK, Cuber P, Bochon B, et al. The levels of sICAM-1, sELAM-1, TNFα and sTNFR1 proteins in patients with colorectal adenocarcinoma in tumor and corresponding normal mucosa[J]. Acta Biochim Pol, 2020, 67(4): 579-585.
25 Al-Salama ZT, Frampton JE. Glycopyrronium/Formoterol: A eeview in COPD[J]. Drugs, 2019, 79(13): 1455-1466.
26 杨忠民, 刘 玻, 王 岚, 等. 比较固定剂量和递减剂量的ICS联合LABA吸入治疗对慢性阻塞性肺疾病患者生活质量的影响[J]. 临床和实验医学杂志, 2019, 18(15): 1617-1621.
27 Singh D, Van den Berg F, Leaker B, et al. Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler[J]. Br J Clin Pharmacol, 2019, 85(4): 729-736.

备注/Memo

备注/Memo:
基金项目: 全军保健专项课题(168J752)
通信作者: 杨九江, Email: kj99p79@sina.com
更新日期/Last Update: 2021-08-20